Kohl Franziska, Laufkötter Oliver, Firth Mike, Krimpenfort Luc, Mangla Priyanka, Ansarizadeh Mohammadhassan, Geylan Gökçe, Eklund Lauri, De Maria Leonardo, Jakobsson Lars, Wiseman John
Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.
Biomed Pharmacother. 2025 Jan;182:117740. doi: 10.1016/j.biopha.2024.117740. Epub 2024 Dec 12.
Vascular anomalies (VA) refer to abnormal blood or lymphatic vessel architecture, most often as a result of dysregulated growth. Venous malformations (VM), a subgroup of VAs, are triggered by activating mutations in the Angiopoietin/TIE2-PI3K/AKT/mTOR signaling pathway with TIE2 L914F (gene name TEK) being one of the most frequent mutations in patients with VMs. Although systemic targeting of the overactivated pathway is possible, it would be a therapeutic advantage to restrict treatment to only the affected lesions. To identify peptides with potential selective binding to TIE2 L914F lesions we applied in vivo phage display to TIE2 L914F-overexpressing endothelial cells (ECs) in a subcutaneous matrigel xenograft mouse model of VMs. By panning for lesion-targeting phages in combination with subcellular fractionation, a screen for cell-penetrating candidate phages was established. Employing Next Generation Sequencing (NGS) and a refined bioinformatic analysis we were able to identify many novel cell-penetrating peptides (CPPs). To pinpoint the most selective and viable CCP candidates a hierarchical clustering algorithm was utilized. This method aggregated CPPs with highly similar sequences into a small number of clusters from which consensus sequences could be derived. Selected candidate CPPs exhibited uptake in TIE2 L914F-expressing human umbilical vein endothelial cells (HUVEC) in culture and were able to deliver siRNA into these cells. In conclusion, our NGS bioinformatic-supported approach led to the identification of novel and selective CPPs capable of transporting a siRNA cargo into targeted cells.
血管异常(VA)是指异常的血管或淋巴管结构,多数情况下是生长失调的结果。静脉畸形(VM)是VA的一个亚组,由血管生成素/TIE2 - PI3K/AKT/mTOR信号通路中的激活突变引发,其中TIE2 L914F(基因名TEK)是VM患者中最常见的突变之一。尽管对过度激活的通路进行全身靶向治疗是可行的,但将治疗仅限于受影响的病变部位将具有治疗优势。为了鉴定与TIE2 L914F病变具有潜在选择性结合的肽,我们在VM的皮下基质胶异种移植小鼠模型中,将体内噬菌体展示应用于过表达TIE2 L914F的内皮细胞(EC)。通过结合亚细胞分级分离筛选靶向病变的噬菌体,建立了一种细胞穿透候选噬菌体的筛选方法。利用下一代测序(NGS)和精细的生物信息学分析,我们能够鉴定出许多新型的细胞穿透肽(CPP)。为了确定最具选择性和可行性的CCP候选物,使用了层次聚类算法。该方法将具有高度相似序列的CPP聚集到少量簇中,从中可以得出共有序列。选定的候选CPP在培养的表达TIE2 L914F的人脐静脉内皮细胞(HUVEC)中表现出摄取能力,并能够将siRNA递送至这些细胞中。总之,我们基于NGS生物信息学支持的方法导致鉴定出能够将siRNA货物转运到靶细胞中的新型选择性CPP。